Literature DB >> 8825570

Canine osteosarcoma: amputation and chemotherapy.

J Berg1.   

Abstract

One of the most important advances in veterinary oncology during the past 10 years has been the use of adjuvant chemotherapy for treatment of the micrometastases of canine osteosarcoma. This article reviews the biologic behavior of osteosarcoma and discusses chemotherapy with the two agents known to be effective: cisplatin and doxorubicin.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8825570     DOI： 10.1016/s0195-5616(96)50010-0

Source DB:  PubMed          Journal:  Vet Clin North Am Small Anim Pract        ISSN： 0195-5616            Impact factor:   2.093


  10 in total

1.  RUNX2 RNA interference inhibits the invasion of osteosarcoma.

Authors:  Heng Zeng; Xiaotao Xu
Journal:  Oncol Lett       Date:  2015-04-20       Impact factor: 2.967

2.  The effect of the bisphosphonate alendronate on viability of canine osteosarcoma cells in vitro.

Authors:  James P Farese; Jenna Ashton; Rowan Milner; Linda-Lee Ambrose; James Van Gilder
Journal:  In Vitro Cell Dev Biol Anim       Date:  2004 Mar-Apr       Impact factor: 2.416

3.  Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs.

Authors:  Carlos O Rodriguez; Torrie A Crabbs; Dennis W Wilson; Virginia A Cannan; Katherine A Skorupski; Nancy Gordon; Nadya Koshkina; Eugenie Kleinerman; Peter M Anderson
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-08       Impact factor: 2.849

Review 4.  What do we know about canine osteosarcoma treatment? Review.

Authors:  M Szewczyk; R Lechowski; K Zabielska
Journal:  Vet Res Commun       Date:  2014-11-26       Impact factor: 2.459

Review 5.  Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics.

Authors:  Siobhan Simpson; Mark David Dunning; Simone de Brot; Llorenç Grau-Roma; Nigel Patrick Mongan; Catrin Sian Rutland
Journal:  Acta Vet Scand       Date:  2017-10-24       Impact factor: 1.695

6.  Comparative oncology approach to drug repurposing in osteosarcoma.

Authors:  Alejandro Parrales; Peter McDonald; Megan Ottomeyer; Anuradha Roy; Frank J Shoenen; Melinda Broward; Tyce Bruns; Douglas H Thamm; Scott J Weir; Kathleen A Neville; Tomoo Iwakuma; Joy M Fulbright
Journal:  PLoS One       Date:  2018-03-26       Impact factor: 3.240

7.  Melarsomine suppresses canine osteosarcoma cell survival via inhibition of Hedgehog-GLI signaling.

Authors:  Aryung Nam; Taewon Kim; Qiang Li; Robert B Rebhun; Hwa-Young Youn; Kyoung-Won Seo
Journal:  J Vet Med Sci       Date:  2019-10-22       Impact factor: 1.267

Review 8.  Understanding the Osteosarcoma Pathobiology: A Comparative Oncology Approach.

Authors:  Jyotika Varshney; Milcah C Scott; David A Largaespada; Subbaya Subramanian
Journal:  Vet Sci       Date:  2016-01-18

9.  The autophagy inhibitor spautin-1, either alone or combined with doxorubicin, decreases cell survival and colony formation in canine appendicular osteosarcoma cells.

Authors:  Courtney R Schott; Latasha Ludwig; Anthony J Mutsaers; Robert A Foster; Geoffrey A Wood
Journal:  PLoS One       Date:  2018-10-29       Impact factor: 3.240

10.  Defucosylated Mouse-Dog Chimeric Anti-EGFR Antibody Exerts Antitumor Activities in Mouse Xenograft Models of Canine Tumors.

Authors:  Guanjie Li; Tomokazu Ohishi; Mika K Kaneko; Junko Takei; Takuya Mizuno; Manabu Kawada; Masaki Saito; Hiroyuki Suzuki; Yukinari Kato
Journal:  Cells       Date:  2021-12-20       Impact factor: 6.600
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.